Open access
Open access
Powered by Google Translator Translator

General Hematology

Cohort Study | Incidence and impact of anticoagulation-associated abnormal menstrual bleeding after VTE

27 Jan, 2023 | 12:04h | UTC

Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism – Blood

Invited Commentary: The burden of heavy menstrual bleeding – Blood

 

Commentary on Twitter

 


Review | Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT)

26 Jan, 2023 | 12:46h | UTC

Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) – Blood

 


RCT | Aspirin noninferior to low-molecular-weight heparin for thromboprophylaxis after a fracture

19 Jan, 2023 | 14:30h | UTC

Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Aspirin as effective as blood thinner injections to prevent deadly complications in patients hospitalized with bone fractures – University of Maryland School of Medicine

Commentary: PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures – TCTMD

 


M-A | Optimal timing of perioperative chemical thromboprophylaxis in elective major abdominal surgery

19 Jan, 2023 | 13:52h | UTC

Optimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)

 


Review | Management of patients with lower-risk myelodysplastic syndromes

19 Jan, 2023 | 13:47h | UTC

Management of patients with lower-risk myelodysplastic syndromes – Blood Cancer Journal

 


Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

18 Jan, 2023 | 14:37h | UTC

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score – European Heart Journal

See calculator: https://vtepredict.com/

 

Commentary on Twitter

 


Retrospective study | Supernumerary sex chromosome aneuploidies are associated with increased risk of VTE

18 Jan, 2023 | 14:22h | UTC

Association of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism – JAMA (free for a limited period)

 


ESMO Guideline | Venous thromboembolism in cancer patients

15 Jan, 2023 | 20:21h | UTC

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology

Related:

Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

 


SR | Laser therapy for retinopathy in sickle cell disease

12 Jan, 2023 | 13:02h | UTC

Laser therapy for retinopathy in sickle cell disease – Cochrane Library

Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library

 


Review | Antithrombotic therapy after bioprosthetic aortic valve replacement

12 Jan, 2023 | 12:51h | UTC

How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review – Thrombosis and Haemostasis

 


Review | Platelet transfusion for trauma resuscitation

11 Jan, 2023 | 14:08h | UTC

Platelet Transfusion for Trauma Resuscitation – Current Trauma Reports

 


Special Issue | American Society of Hematology Education Program (series of open-access review articles)

10 Jan, 2023 | 14:26h | UTC

Homepage: American Society of Hematology Education Program – Hematology

 


Chronic lymphocytic leukemia treatment algorithm 2022

10 Jan, 2023 | 14:05h | UTC

Chronic lymphocytic leukemia treatment algorithm 2022 – Blood Cancer Journal

 


Updated Guidance | Acute, periprocedural and long-term antithrombotic therapy in older adults.

16 Dec, 2022 | 13:51h | UTC

Acute, periprocedural and long-term antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis – European Heart Journal

Commentary: Antithrombotic Therapy in Older Adults: Key Points – American College of Cardiology

 


RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.

16 Dec, 2022 | 13:15h | UTC

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial – Gut

 


Major hemorrhage: past, present and future.

13 Dec, 2022 | 14:05h | UTC

Major haemorrhage: past, present and future – Anaesthesia

 


M-A | Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage.

9 Dec, 2022 | 13:17h | UTC

Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 


Preliminary study suggests that Edoxaban is a safe alternative for preventing thromboembolism in pediatric patients with cardiac disease.

9 Dec, 2022 | 13:07h | UTC

Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Advancing Anticoagulation for Children With Cardiac Disease – Journal of the American College of Cardiology

Commentary: Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease – ENNOBLE-ATE – American College of Cardiology

Related: [Abstract Only] Randomized Trial: Direct Oral Anticoagulant Similarly Effective as Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children

 


Cohort Study | Cutaneous involvement in catastrophic antiphospholipid syndrome.

8 Dec, 2022 | 12:53h | UTC

Cutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients – JAMA Dermatology (free for a limited period)

 

Commentary on Twitter

 


RCT | Fostamatinib for the treatment of patients with primary immune thrombocytopenia.

7 Dec, 2022 | 14:18h | UTC

Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study – British Journal of Haematology

 


RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.

2 Dec, 2022 | 14:24h | UTC

Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence

 

Commentary on Twitter

 


Cohort Study | Trends and risk factors for venous thromboembolism among hospitalized medical patients.

29 Nov, 2022 | 14:04h | UTC

Trends and Risk Factors for Venous Thromboembolism Among Hospitalized Medical Patients – JAMA Network Open

 

Commentary on Twitter

 


RCT | Anticoagulation for 3 months reduces recurrence rates vs. treatment for 6 weeks in patients with isolated distal DVT.

24 Nov, 2022 | 13:34h | UTC

Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial – The BMJ

News Release: Extending anti-clotting treatment after distal DVT reduces further clot risk – BMJ Newsroom

 


SR | Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.

24 Nov, 2022 | 13:24h | UTC

Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding – Cochrane Library

Summary: Prothrombin complex concentrate in the treatment of bleeding that occurs with heart surgery – Cochrane Library

 


RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome.

22 Nov, 2022 | 13:12h | UTC

Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome – Blood 

 


Stay Updated in Your Specialty

No spam, just news.